US Bancorp
CTNM

US Bancorp’s Contineum Therapeutics CTNM Stock Holding History

US Bancorp’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61K Buy
+123
New +$1.65K ﹤0.01% 3850

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

US Bancorp's CTNM Position: Q1 2026 in Review

US Bancorp opened a new position in Contineum Therapeutics (CTNM) in Q1 2026: 123 shares worth $1.61K. The stake represents ﹤0.01% of the portfolio and ranks #3850 among its holdings.

90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • US Bancorp held 123 shares of Contineum Therapeutics worth $1.61K as of Q1 2026.
  • Contineum Therapeutics was a new US Bancorp position in Q1 2026.
  • Contineum Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3850 holding.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.